DE60142079D1 - Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird - Google Patents

Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird

Info

Publication number
DE60142079D1
DE60142079D1 DE60142079T DE60142079T DE60142079D1 DE 60142079 D1 DE60142079 D1 DE 60142079D1 DE 60142079 T DE60142079 T DE 60142079T DE 60142079 T DE60142079 T DE 60142079T DE 60142079 D1 DE60142079 D1 DE 60142079D1
Authority
DE
Germany
Prior art keywords
protein
guanosintriphosphate
butenged
gtp
searching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142079T
Other languages
English (en)
Inventor
T Maruyama
Takao Nakamura
Hiraku Itadani
K Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27345218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60142079(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Application granted granted Critical
Publication of DE60142079D1 publication Critical patent/DE60142079D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60142079T 2000-11-17 2001-10-30 Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird Expired - Lifetime DE60142079D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000351741 2000-11-17
JP2001038619 2001-02-15
JP2001077000 2001-03-16
PCT/JP2001/009512 WO2002040669A1 (fr) 2000-11-17 2001-10-30 Bg37, nouvelle proteine du recepteur couple aux proteines g de liaison de guanosine triphosphate (gtp)

Publications (1)

Publication Number Publication Date
DE60142079D1 true DE60142079D1 (de) 2010-06-17

Family

ID=27345218

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142079T Expired - Lifetime DE60142079D1 (de) 2000-11-17 2001-10-30 Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird

Country Status (8)

Country Link
US (3) US7198914B2 (de)
EP (1) EP1347052B1 (de)
JP (1) JP4003069B2 (de)
AT (1) ATE466939T1 (de)
AU (1) AU2001296033A1 (de)
CA (1) CA2429214A1 (de)
DE (1) DE60142079D1 (de)
WO (1) WO2002040669A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354726B2 (en) 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
GB0208407D0 (en) * 2001-10-01 2002-05-22 Aventis Pharma Inc A novel G protein-coupled receptor, GAVE10
JP2005520498A (ja) * 2001-12-17 2005-07-14 ノバルティス アクチエンゲゼルシャフト 新規ｇタンパク質共役受容体およびそのｄｎａ配列
WO2004043468A1 (ja) * 2002-11-12 2004-05-27 Takeda Pharmaceutical Company Limited スクリーニング方法
AU2003298111A1 (en) * 2002-11-22 2004-06-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
JP2007532135A (ja) * 2004-04-13 2007-11-15 アリーナ ファーマシューティカルズ， インコーポレイテッド 高血糖症および関連障害の処置のための、ヒトｇタンパク質共役レセプターおよびそのモジュレーター
JPWO2006070718A1 (ja) * 2004-12-27 2008-06-12 萬有製薬株式会社 全胆汁酸プール量の増減に伴う疾患又は脂質代謝性疾患に対する薬剤及び、それら薬剤のスクリーニング方法
US8366650B2 (en) 2005-10-24 2013-02-05 Satiogen Pharmaceuticals, Inc. Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
NZ588737A (en) * 2008-03-31 2012-05-25 Univ Columbia Methods of diagnosing, preventing and treating bone mass diseases
EP2322222A4 (de) * 2008-08-07 2011-12-21 Takeda Pharmaceutical Therapeutikum für reizdarmsyndrom
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
JP2012509891A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
WO2011053977A1 (en) 2009-11-02 2011-05-05 The Trustees Of Columbia University In The City Of New York Compounds and methods for inhibiting serotonin synthesis
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09268A (ja) 1994-08-11 1997-01-07 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
JP2000189171A (ja) 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd 新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
CA2368216A1 (en) 1999-03-25 2000-10-05 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate (gtp)-binding protein-coupled receptor proteins, bg3
JP3221607B2 (ja) 1999-06-08 2001-10-22 学校法人加計学園 置換フェニル化合物の合成方法
JP3451338B2 (ja) 1999-07-30 2003-09-29 株式会社シギヤ精機製作所 研削盤に於ける砥石径測定装置
JP2001077000A (ja) 1999-09-02 2001-03-23 Nikon Corp パターンの分割方法及び半導体デバイスの製造方法
AU2398501A (en) 1999-12-20 2001-07-03 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate-binding protein-coupled receptor protein, bg26
EP1273659A4 (de) 2000-04-12 2004-04-21 Takeda Chemical Industries Ltd G-protein gekoppeltes rezeptorprotein und dessen dna
AU2001277963A1 (en) * 2000-07-21 2002-02-05 Millennium Pharmaceuticals, Inc. 65494, a human g-protein-coupled receptor family member and uses thereof
JP2004516817A (ja) * 2000-07-27 2004-06-10 インサイト・ゲノミックス・インコーポレイテッド Ｇタンパク質共役受容体
JP2002112793A (ja) * 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
DE60226414D1 (de) 2001-02-20 2008-06-19 Bayer Healthcare Ag Menschlicher g-protein gekoppelter rezeptor
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7354726B2 (en) * 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
EP1382678B1 (de) * 2001-04-25 2008-08-27 Astellas Pharma Inc. Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung

Also Published As

Publication number Publication date
US8076455B2 (en) 2011-12-13
JP4003069B2 (ja) 2007-11-07
ATE466939T1 (de) 2010-05-15
EP1347052A1 (de) 2003-09-24
WO2002040669A1 (fr) 2002-05-23
US7198914B2 (en) 2007-04-03
AU2001296033A1 (en) 2002-05-27
CA2429214A1 (en) 2003-05-15
US7723046B2 (en) 2010-05-25
US20100184236A1 (en) 2010-07-22
EP1347052A4 (de) 2006-07-19
US20070141642A1 (en) 2007-06-21
US20040086898A1 (en) 2004-05-06
EP1347052B1 (de) 2010-05-05
JPWO2002040669A1 (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
DE60142079D1 (de) Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird
Sawamura et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains.
Keirsebilck et al. Molecular cloning of the human p120ctnCatenin gene (CTNND1): Expression of multiple alternatively spliced isoforms
Strehler et al. Peptide sequence analysis and molecular cloning reveal two calcium pump isoforms in the human erythrocyte membrane.
Lewis et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor
Wang et al. The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype.
Gorn et al. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction.
CN1329511C (zh) 非内源的被组成型活化的人g蛋白偶联的受体
ES2618785T3 (es) Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
DE69638022D1 (de) Aus wirbeltieren und darauf basierende verfahren
Almeida et al. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32. 1, is amplified and overexpressed in malignant gliomas
Ollendorff et al. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins
Chang et al. Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif
Cha et al. The cDNA sequence of mouse LAMP-2. Evidence for two classes of lysosomal membrane glycoproteins.
FI920027A0 (fi) Receptorer foer fibroblasttillvaextfaktorer.
JPH10507776A (ja) トロンボポエチン受容体に結合するペプチドおよび化合物
Sugita et al. Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement
Engeland et al. Cloning and functional expression of rat ether-a-go-go-like K+ channel genes
Schäcke et al. Immunoglobulin‐like domain is present in the extracellular part of the receptor tyrosine kinase from the marine sponge Geodia cydonium
Racevskis et al. Molecular cloning of LMO4, a new human LIM domain gene
AU764158B2 (en) Odorant receptors
Schöneberg et al. A novel subgroup of class I G-protein-coupled receptors
Ikemoto et al. Identification and molecular characterization of three GnRH ligands and five GnRH receptors in the spotted green pufferfish
EP1297003A2 (de) Eine rekombinante zelllinie, die gpcrx11 exprimieren und die einen funktionellen rezeptor für angiopeptin darstellt und sich für das screening von agonisten und antagonisten eignet
CA2316283A1 (en) Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein

Legal Events

Date Code Title Description
8363 Opposition against the patent